secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0000950170-22-019164
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics appoints Dana Pizzuti, M.D. as Chief Development Officer effective Sept 30, 2022
--------------------------------------------------------------------------------

- Dr. Pizzuti appointed CDO effective Sept 30, 2022; annual base salary $525,000 and target annual bonus of 40% of base.
- She has over 30 years pharma experience, including leading regulatory at Gilead and Ascendis; helped secure marketing approvals for 15 drugs.
- Expected equity grants: stock option for 230,000 shares (25% vest Sept 30, 2023, then 36 monthly) and 12,500 RSUs (vest March 30, 2023).
- Signing bonus of $95,000 and relocation assistance; severance includes 9-12 months base salary depending on termination scenario.
- Her appointment supports upcoming Phase 3 topline data for paltusotine in acromegaly and preparation of marketing authorization applications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022019164/0000950170-22-019164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022019164/crnx-20221003.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-019164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer